Pharmaceutical companies have filed numerous lawsuits to block the law, to no success.
The negotiated prices, announced Aug. 15, would have saved Medicare about $6 billion for more than 9 million people who use these medications.
Compared with 2023 list prices, the negotiated prices offer savings between 38% and 79%.
The negotiated prices are for a 30-day supply, and the new prices will take effect Jan. 1, 2026.
1. Januvia, a Type 2 diabetes drug from Merck:
List price in 2023: $527
Negotiated price: $113
Part D cost from 2023: $4.09 billion
Discount: 79%
2. Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen, and NovoLog PenFill; Type 2 diabetes drugs from Novo Nordisk:
List price in 2023: $495
Negotiated price: $119
Discount: 76%
Part D cost from 2023: $2.61 billion
3. Farxiga, a medication for Type 2 diabetes, heart failure and chronic kidney disease from AstraZeneca:
List price in 2023: $556
Negotiated price: $178
Discount: 68%
Part D cost from 2023: $4.34 billion
4. Enbrel, a therapy for rheumatoid arthritis, psoriasis and psoriatic arthritis from Immunex:
List price in 2023: $7,106
Negotiated price: $2,355
Discount: 67%
Part D cost from 2023: $2.95 billion
5. Jardiance, a Type 2 diabetes and heart failure drug from Boehringer Ingelheim:
List price in 2023: $573
Negotiated price: $197
Discount: 66%
Part D cost from 2023: $8.84 billion
6. Stelara, a drug for psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis from Janssen:
List price in 2023: $13,836
Negotiated price: $4,695
Discount: 66%
Part D cost from 2023: $2.99 billion
7. Xarelto, a blood clot preventive drug and treatment, and a medication for coronary and peripheral artery disease from Janssen:
List price in 2023: $517
Negotiated price: $197
Discount: 62%
Part D cost from 2023: $6.31 billion
8. Eliquis, a preventive drug and treatment for blood clots from Bristol Myers Squibb:
List price in 2023: $521
Negotiated price: $231
Discount: 56%
Part D cost from 2023: $18.28 billion
9. Entresto, a heart failure drug from Novartis:
List price in 2023: $628
Negotiated price: $295
Discount: 53%
Part D cost from 2023: $3.43 billion
10. Imbruvica, a blood cancer treatment from Pharmacyclics:
List price in 2023: $14,934
Negotiated price: $9,319
Discount: 38%
Part D cost from 2023: $2.37 billion
